Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Summit Technology (BEAM) -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (1000)	7/20/1998 8:29:00 AM
From: Mo	Read Replies (2) \| Respond to of 1386

I found the following post on the VISX thread, No. 654 by admr: " the use of the excimer laser in hyperopia, presbyopia is a difficult procedure, invasive and not without complications. The Sunrise Tech Laser using LTK Holmium laser will be the laser of choice for the above indications. It is much easier to use, less complications I believe they are submitting to the FDA in October with approval in 1999. The excimer will get approval this year but for hyperopia, presbopia and overcorrection resulting from PRK and Lasik treatments for myopia its clear that the Sunrise Laser will be used. The excimer will be for these indications be obsolete in six months. " Then in another post, it says : " Check the SNRS 10K, it notes that Summit has a holmium laser system, but that SNRS believes that it may violate certain of Sunrise's patents. Furthermore, they believe that their laser is superior and currenly none of the Company's competitors is currently engaged in the United States in clinical trials to approve their LTK devices for treating hyperopia. What does that do to BEAM? It seems they are beaten by VISX in myopia ( as current earnings and market action would indicate), and will be beaten by Sunrise in hyperopia. What is left for BEAM ?